false
0001692415
0001692415
2026-08-25
2026-08-25
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 OR 15(d) of The
Securities
Exchange Act of 1934
Date
of Report (Date of earliest event reported): August 25, 2026
CO-DIAGNOSTICS,
INC.
(Exact
name of registrant as specified in its charter)
| Utah |
|
001-38148 |
|
46-2609363 |
(State
or other jurisdiction
of
incorporation) |
|
(Commission
File
Number) |
|
(IRS
Employer
Identification
No. ) |
2401
S. Foothill Drive, Suite D, Salt Lake City Utah 84109
(Address
of principal executive offices) (Zip Code)
(801)
438-1036
Registrant’s
telephone number, including area code
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
| ☐ |
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
|
| ☐ |
Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
|
| ☐ |
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
|
| ☐ |
Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
| Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
| Common Stock, par value
$0.001 per share |
|
CODX |
|
The Nasdaq Capital Market |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
8.01. Other Events.
In
August 2026, Co-Diagnostics, Inc. (the “Company”) entered into a material transfer agreement with ReadyGo Diagnostics Ltd
(“ReadyGo”) to evaluate the potential compatibility of certain ReadyGo sample collection and preparation technologies with
the Company’s Co-Dx PCR platform.
ReadyGo
develops sample collection and preparation technologies designed to simplify the front end of diagnostic testing, including technologies
intended to collect biological samples, lyse cells or other biological material, stabilize nucleic acids and prepare samples for downstream
molecular analysis. The Company’s Co-Dx PCR platform is being developed to provide real-time PCR testing in decentralized and point-of-care
settings through a compact instrument and proprietary test cups.
Under
the material transfer agreement, ReadyGo has agreed to provide certain of its sampling materials to the Company for feasibility studies,
including evaluation and compatibility testing with the Company’s products. The Company believes ReadyGo’s sample collection
and preparation technologies may be complementary to the Co-Dx PCR platform and its objective of expanding access to high-quality molecular
diagnostics outside traditional laboratory settings. By evaluating technologies designed to simplify the collection, stabilization and
preparation of biological samples for molecular analysis, the Company is exploring opportunities to further streamline the sample-to-result
workflow and enhance the usability of its Co-Dx PCR platform in decentralized testing environments.
The
evaluation activities are preliminary in nature, and the material transfer agreement does not obligate either party to enter into any
development, supply, commercialization or other commercial arrangement. There can be no assurance that the evaluation activities will
result in any additional agreement or commercial relationship between the parties.
The
Co-Dx PCR platform and associated tests are subject to review by the U.S. Food and Drug Administration and/or other applicable regulatory
authorities and are not currently available for sale.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, hereunto duly authorized.
| |
CO-DIAGNOSTICS,
INC. |
| |
|
|
| Date:
September 15, 2026 |
By: |
/s/
Dwight Egan |
| |
Name: |
Dwight
Egan |
| |
Title: |
Chief
Executive Officer |
| |
|
(Principal
Executive Officer) |
